CY9D Stock Overview
A pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Microbot Medical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.85 |
| 52 Week High | US$1.79 |
| 52 Week Low | US$0.70 |
| Beta | 1.63 |
| 11 Month Change | -5.73% |
| 3 Month Change | -1.63% |
| 1 Year Change | -28.26% |
| 33 Year Change | -82.86% |
| 5 Year Change | -80.85% |
| Change since IPO | -99.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| CY9D | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.0% | -1.0% | -0.02% |
| 1Y | -28.3% | -7.3% | 8.2% |
Return vs Industry: CY9D underperformed the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: CY9D underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| CY9D volatility | |
|---|---|
| CY9D Average Weekly Movement | 9.1% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CY9D's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CY9D's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 22 | Harel Gadot | microbotmedical.com |
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
Microbot Medical Inc. Fundamentals Summary
| CY9D fundamental statistics | |
|---|---|
| Market cap | €15.12m |
| Earnings (TTM) | -€10.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs CY9D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CY9D income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.21m |
| Earnings | -US$11.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CY9D perform over the long term?
See historical performance and comparison